Oxbryta Union européenne - français - EMA (European Medicines Agency)

oxbryta

pfizer europe ma eeig  - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.

Apexxnar Union européenne - français - EMA (European Medicines Agency)

apexxnar

pfizer europe ma eeig - pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 3, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6a, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 8, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 10a, pneumococcal polysaccharide serotype 11a, pneumococcal polysaccharide serotype 12f, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 15b, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19a, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 22f, pneumococcal polysaccharide serotype 23f, pneumococcal polysaccharide serotype 33f - infections pneumococciques - vaccins - active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. voir les sections 4. 4 et 5. 1 pour des informations sur la protection contre les sérotypes pneumococciques spécifiques. apexxnar should be used in accordance with official recommendations. .

Bosentan Accord 125 mg compr. pellic. Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bosentan accord 125 mg compr. pellic.

accord healthcare b.v. - bosentan monohydraté - eq. bosentan 125 mg - comprimé pelliculé - bosentan

Bosentan Accord 62,5 mg compr. pellic. Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bosentan accord 62,5 mg compr. pellic.

accord healthcare b.v. - bosentan monohydraté 62,5 mg - eq. bosentan 62,5 mg - comprimé pelliculé - bosentan

Co-Nebivolol Accord 5 mg - 12,5 mg compr. pellic. Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

co-nebivolol accord 5 mg - 12,5 mg compr. pellic.

accord healthcare b.v. - chlorhydrate de nébivolol 5,45 mg - eq. nébivolol 5 mg; hydrochlorothiazide 12,5 mg - comprimé pelliculé - nebivolol and thiazides

Co-Nebivolol Accord 5 mg - 25 mg compr. pellic. Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

co-nebivolol accord 5 mg - 25 mg compr. pellic.

accord healthcare b.v. - chlorhydrate de nébivolol 5,45 mg - eq. nébivolol 5 mg; hydrochlorothiazide 25 mg - comprimé pelliculé - nebivolol and thiazides

Naltrexone Accord 50 mg compr. pellic. Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

naltrexone accord 50 mg compr. pellic.

accord healthcare b.v. - chlorhydrate de naltrexone 50 mg - comprimé pelliculé - naltrexone

Abrysvo Union européenne - français - EMA (European Medicines Agency)

abrysvo

pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - infections respiratoires du virus syncytial - vaccins - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. voir les sections 4. 2 et 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. l'utilisation de ce vaccin doit être en conformité avec les recommandations officielles.

Litfulo Union européenne - français - EMA (European Medicines Agency)

litfulo

pfizer europe ma eeig - ritlecitinib tosilate - alopecia areata - immunosuppresseurs - litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.